Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Thursday, September 19, 2024, 13:00 Hrs [IST] Novarti ...

Atlantic City's mayor is now the latest elected official in a string of others from the New Jersey beachside gambling ...

The FDA’s clearance could double Kisqali’s breast cancer market. Elsewhere, Novo is exploring new ways to deliver genetic therapies and Bain is funding a growing CDMO.

Sen. Bernie Sanders has been probing the high prices that Novo charges for Ozempic and Wegovy. Yesterday, he share that ...

The drug's approval for a broader population should further fuel sales. Regulatory reviews for Kisqali as an EBC treatment ...

“The FDA approval of Kisqali for this early breast cancer population, including those with NO [hasn't spread to nearby lymph ...

Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhi ...

Drinking several cups of caffeinated coffee or tea a day may protect against Type 2 diabetes, coronary heart disease and ...

Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 ...

Regulatory reviews for ribociclib among patients with early breast cancer are continuously ongoing to include the EMA and China. 1. FDA approves Kisqali with an aromatase inhibitor and Kisqali Femara ...